Literature DB >> 26337366

Foamy Macrophage Deposition in Lymph Nodes Mimicking Lung Cancer Recurrence Diagnosed via Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration.

Qiaoling Zhou1, Douglas G West, Golda Shelley-Fraser, Andrew R L Medford.   

Abstract

The radiological finding of mediastinal lymph node enlargement following surgery for lung cancer often signifies locoregional recurrence. The use of oxidised cellulose haemostatic agents (OCHAs) during staging mediastinoscopy is common. We report a case of 18-fluorodeoxyglucose-avid subcarinal lymphadenopathy in a patient in whom OCHAs had been used at mediastinoscopy 5 months earlier. Histopathological examination of suspected nodal recurrence is facilitated by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). The technique is particularly useful after previous mediastinoscopy, when repeat surgical exploration can be challenging. EBUS-TBNA samples showed extensive foamy macrophage deposition, with no evidence of malignancy. The association between the use of OCHAs and subsequent intranodal foamy macrophage deposition is new. Clinicians should consider this possibility in the differential diagnosis of mediastinal lymphadenopathy after surgical exploration, where OCHAs have been left in situ; it remains important to resample the lymph nodes before assuming disease recurrence to prevent unnecessary treatment.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 26337366     DOI: 10.1159/000438491

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  3 in total

1.  Rab11a promotes proliferation and invasion through regulation of YAP in non-small cell lung cancer.

Authors:  Qianze Dong; Lin Fu; Yue Zhao; Yaming Du; Qingchang Li; Xueshan Qiu; Enhua Wang
Journal:  Oncotarget       Date:  2017-04-25

2.  Transbronchial and transesophageal fine-needle aspiration using a single ultrasound bronchoscope in the diagnosis of locoregional recurrence of surgically-treated lung cancer.

Authors:  José Sanz-Santos; Pere Serra; Felipe Andreo; Mohamed Torky; Carmen Centeno; Teresa Morán; Enric Carcereny; Esther Fernández; Samuel García-Reina; Juan Ruiz-Manzano
Journal:  BMC Pulm Med       Date:  2017-02-28       Impact factor: 3.317

3.  TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3β/β-catenin signaling in non-small cell lung cancer.

Authors:  Li Liu; Xiao-Ming Zhou; Fang-Fei Yang; Yuan Miao; Yan Yin; Xue-Jun Hu; Gang Hou; Qiu-Yue Wang; Jian Kang
Journal:  Oncotarget       Date:  2017-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.